Pharmacokinetic Comparison Between L & D, L-BPA. Fructose in a Murine Melanoma Model and in Human Patients with Metastatic Melanoma

  • Douglas E. Moore
  • Julia L. Mallesch
  • William H. McCarthy
  • Barry J. Allen


Various drugs have been developed and trialed for boron neutron capture therapy (BNCT) but p-borono-phenylalanine (BPA) is one of the most successful compounds to date. BPA was originally developed as a selective targeting drug for BNCT of brain tumours on the basis that cancer cells require increased quantities of amino acids in order to maintain their faster metabolism compared to normal cells.1 Melanoma cells actively transport and metabolise aromatic amino acids such as phenylalanine and tyrosine for use as precursors in the synthesis of the pigment, melanin. BPA, being a phenylalanine derivative, is believed to exploit this mechanism resulting in the selective uptake in melanoma tumours and the successful application of BNCT in animals and some human patients.2–5


Metastatic Melanoma Boron Concentration Boronic Acid Boron Neutron Capture Therapy Selective Uptake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Snyder FIR, Reedy AJ, Lennarz W. Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine, J. Am. Chem. Soc. 80: 835–838, 1958.CrossRefGoogle Scholar
  2. 2.
    Mishima Y, Honda O, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino K. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma seeking B-10 compound, Lancet 1989 ii: 388–389.Google Scholar
  3. 3.
    Allen Bi, Corderoy-Buck S, Mallesch JL, Crotty K, Moore DE. Local control of subcutaneous melanoma xenografts in nude mice by neutron capture therapy, Melanoma Res. 2: 253–262, 1992.PubMedCrossRefGoogle Scholar
  4. 4.
    Coderre JA, Glass JD, Fairchild RG, Roy U, Cohen S, Fand I. Selective targeting ofboronophenylalanine to melanoma in Balb/c mice for neutron capture therapy, Cancer Res. 47: 6377–6383, 1987.PubMedGoogle Scholar
  5. 5.
    Mallesch JL, Moore DE, Allen BJ, McCarthy WH, Jones R, Stening W. The pharmacokinetics of p-boronophenylalanine.fructose in human patients with glioma and metastatic melanoma. Int. J. Rad. One. Biol. Phys. 28: 1183–1188, 1994.CrossRefGoogle Scholar
  6. 6.
    Albert A, “Selective Toxicity” 7th Ed. Chapman AND Hall, London, 1985, pp. 490–500.CrossRefGoogle Scholar
  7. 7.
    Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumours other than melanoma, Cancer Res. 50: 138–141, 1990.PubMedGoogle Scholar
  8. 8.
    Ichihashi M, Fukuda H, Brown JK, Mountford MH, Allen BJ, Wilson JG, Mishima Y. In-vitro evaluation of 1°B-BPA for melanoma at Moata–Joint work between Japan and Australia BNCT research teams, in: “Progress in Neutron Capture Therapy for Cancer,” BJ Allen, DE Moore, BY Harrington, eds. Plenum Press, New York, 1992, pp. 387–390.CrossRefGoogle Scholar
  9. 9.
    Coderre JA, Packer S, Greenberg D, Micca PL, Joel DD, Saraf S. Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine, in: “Progress in Neutron Capture Therapy for Cancer,” BJ Allen, DE Moore, BV Harrington, eds. Plenum Press, New York, 1992, pp. 463–468.CrossRefGoogle Scholar
  10. 10.
    Coderre JA. A phase-1 biodistribution study of p-boronophenylalanine, in: “Boron Neutron Capture Therapy,” D Gabel, R Moss, eds. Plenum Press, New York, 1992, pp. I I I - 121.Google Scholar
  11. 11.
    Mori, Y, Susuki K, Yoshino K, Kakihana H. Complex formation of p-boronophenylalanine with some monosaccharides. Pigment Cell Res. 2: 273–277, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Tamat SR, Moore DE, Allen BJ. Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry. Anal. Chem. 59: 2161–2164, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Douglas E. Moore
    • 1
  • Julia L. Mallesch
    • 1
  • William H. McCarthy
    • 2
  • Barry J. Allen
    • 1
    • 3
  1. 1.Department of PharmacyUniversity of SydneyAustralia
  2. 2.Sydney Melanoma UnitRoyal Prince Alfred HospitalAustralia
  3. 3.St George Cancer Care CentreSt George HospitalKogarahAustralia

Personalised recommendations